Hudson Bay Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Hudson Bay Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200	Closed	-$2.21K	–	1198
2025 Q3	$2.21K	Buy	+200	New	+$2.18K	﹤0.01%	1193
2023 Q1	–	Sell	-100,000	Closed	-$432K	–	865
2022 Q4	$432K	Hold	100,000	–	–	﹤0.01%	727
2022 Q3	$752K	Hold	100,000	–	–	0.01%	869
2022 Q2	$1M	Hold	100,000	–	–	0.01%	916
2022 Q1	$1.24M	Buy	+100,000	New	+$1.55M	0.02%	796
2020 Q1	–	Sell	-10,000	Closed	-$203K	–	497
2019 Q4	$203K	Sell	10,000 -170,000	-94%	-$1.57M	﹤0.01%	369
2019 Q3	$961K	Buy	+180,000	New	+$1.09M	0.03%	323

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudson Bay Capital Management's AUPH Position: Q1 2026 in Review

Hudson Bay Capital Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 85,000 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #848.

Hudson Bay Capital Management first reported a position in AUPH in Q2 2017 and has held it in 36 quarters since. The position peaked at $10.1M in Q1 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Hudson Bay Capital Management held 85,000 shares of Aurinia Pharmaceuticals worth $1.26M as of Q1 2026.
Hudson Bay Capital Management left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #848 holding.
Hudson Bay Capital Management first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
Hudson Bay Capital Management's Aurinia Pharmaceuticals position peaked at $10.1M in Q1 2021.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.